Tag: Savolitinib
-
Hutchmed Secures NDA Acceptance in China for Savolitinib MET Inhibitor Based on Phase II Data
Hutchmed Announces NDA Acceptance in China for Savolitinib MET Inhibitor Hutchmed, a leading biopharma company focused on cancer therapies, has announced that its regulatory submission for Savolitinib has been accepted as a New Drug Application (NDA) in China. This development comes on the heels of a positive Phase II registration study in Chinese patients and…
-
HUTCHMED Wins Priority NDA Acceptance in China for Savolitinib-Based MET Inhibition Therapy
HUTCHMED Advances Savolitinib with Priority NDA Acceptance in China HUTCHMED, a global biopharma company focused on oncology and immunology, announced that the National Medical Products Administration (NMPA) in China has accepted its new drug application (NDA) for Savolitinib with priority review status. This move follows the company’s recent positive Phase II registration study data in…
-
Hutchmed Wins Priority NDA Acceptance in China for Savolitinib After Positive Phase II Data
Overview: Hutchmed Moves Forward with Savolitinib in China Hutchmed (Hydrogenated Medicine) has announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Savolitinib with priority review. This milestone follows a sequence of supportive data, including a positive Phase II registration study conducted in Chinese patients and a 2023 Breakthrough…